FKBP52-Tau Interaction Screening for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurological disorders involving Tau dysfunction, such as Alzheimer's disease, lack effective methods to modulate the detrimental effects of pathogenic Tau, and there is a need for novel therapeutic approaches that target the molecular mechanisms controlling Tau structure and function.
Innovation Solution
A direct and specific interaction between the immunophilin FKBP52 and Tau protein has been discovered, providing a new target for therapeutic intervention, with methods developed to screen for molecules that modulate this interaction to prevent and treat neurological disorders, including Alzheimer's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for neurological disorders involving Tau dysfunction, then treatment is provided, but they lack effective methods to modulate the detrimental effects of pathogenic Tau
Solution Approach 1:
The patent introduces FKBP52 as an intermediary protein that mediates the interaction between pathogenic Tau and cellular components. By targeting this intermediary protein, the therapy can modulate the detrimental effects of Tau without directly confronting the aggregated Tau itself, thereby improving therapeutic effectiveness while maintaining adaptability to different Tau pathologies
Solution Approach 2:
The invention extracts and isolates the FKBP52-Tau interaction as a specific therapeutic target, separating it from the complex overall Tau pathology. This allows therapies to specifically modulate the harmful interaction between FKBP52 and pathogenic Tau while leaving other Tau functions intact, thus improving reliability without sacrificing versatility
2Reliability
If novel therapeutic approaches targeting molecular mechanisms controlling Tau structure and function are developed, then effectiveness is improved, but device complexity and screening requirements increase
Solution Approach 1:
FKBP52 serves as a measurable intermediary that provides a concrete biomarker for screening purposes. By focusing on detecting FKBP52-Tau interactions rather than directly measuring complex Tau structural changes, the screening methodology becomes more tractable while still capturing the essential molecular mechanisms of Tau pathogenicity
Solution Approach 2:
The patent replaces complex mechanical or structural assays for detecting Tau pathology with biochemical interaction assays based on FKBP52 binding. This substitution simplifies the screening process by using well-established biochemical techniques (such as binding assays and immunodetection) rather than requiring complex structural biology methods
3Adaptability or versatility
If FKBP52-Tau interaction is targeted for therapeutic intervention, then new therapeutic strategies are identified, but diagnostic and monitoring capabilities must be developed
Solution Approach 1:
FKBP52 acts as a detectable intermediary that provides a clear diagnostic target. The FKBP52-Tau interaction produces measurable signals (such as binding affinity changes or co-immunoprecipitation patterns) that can be detected using standard biochemical assays, making diagnostic development more straightforward while enabling versatile therapeutic targeting
Solution Approach 2:
The patent employs detection methods that utilize signal changes (such as fluorescence, colorimetric responses, or radiometric signals) to indicate FKBP52-Tau interaction. These signal changes provide clear, quantifiable readouts for both diagnostic purposes and therapeutic monitoring, reducing the difficulty of detection while maintaining therapeutic versatility
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3B
AI summary
The invention relates generally to neuroprotection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease). The invention describes a direct interaction between proteins FKBP52 and Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction comprising the following steps: a) determining the ability of a candidate compound, to modulate the interaction between a Tau polypeptide and a FKBP52 polypeptide and b) selecting positively the candidate compound that modulates said interaction. The present invention finally relates to diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction.